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Simple and Complex ABCR: Genetic Predisposition to Retinal Disease
Rando Allikmets
Departments of Ophthalmology and Pathology, Columbia University, New York
Diseases of the retina include a wide spectrum of pho-
toreceptor-affecting phenotypes that have been mapped
to 1120 loci on the human genome (RetNet Retinal In-
formation Network). Currently, less than half of the
causal genes have been identified (RetNet Retinal In-
formation Network), although substantial progress has
been made in determining the genetic basis of monogenic
eye disorders. Mutations in new genes that are respon-
sible for some form of retinal degeneration are identified
on a regular basis. The vast majority of these genes are
involved in rare phenotypes in a limited numbers of
patients.
When the ATP-binding cassette (ABC)–transporter
gene, ABCR, was cloned and characterized in 1997 as
the causal gene for autosomal recessive Stargardt disease
(Allikmets et al. 1997b), it seemed as if just another
missing link had been added to the extensive table of
genetic determinants of rare monogenic retinal dystro-
phies. Now, 13 years later, mutations in the ABCR gene
(also called “ABCA4”) continue to emerge as one of the
predominant determinants of a wide variety of retinal-
degeneration phenotypes.ABCR has caused exciting and
sometimes intense discussions among ophthalmic ge-
neticists, resulting in 150 publications during this brief
period of time. Now, in the current issue of the Journal,
two more studies report interesting new data on ABCR
genetics (Maugeri et al. 2000 [in this issue]; Rivera et
al. 2000 [in this issue]).
In the following brief editorial, I attempt to summarize
our current knowledge of the role of ABCR in retinal
disease. Extensive genetic and functional studies allow
the connection of many pieces of the ABCR puzzle into
a picture that is emerging into focus.
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ABCR in Retinal Dystrophies
In 1997, several laboratories independently described
ABCR as the causal gene for Stargardt disease/fundus
flavimaculatus (STGD1 [MIM 248200]) (Allikmets et al.
1997b; Azarian and Travis 1997; Illing et al. 1997).
Autosomal recessive STGD (arSTGD) is a juvenile-onset
macular dystrophy associated with rapid central visual
impairment, progressive bilateral atrophy of the foveal
retinal pigment epithelium (RPE), and characteristic fre-
quent appearance of orange-yellow flecks around the
macula and/or the midretinal periphery. There is no de-
finitive evidence of genetic heterogeneity of arSTGD; all
families segregating the disorder have been linked to the
ABCR locus on human chromosome 1p13-p22 (Kaplan
et al. 1993; Anderson et al. 1995). Consequently, the
role of theABCR gene in arSTGD has not been disputed,
even despite a relatively low (usually ∼60%) mutation-
detection rate in ABCR in patients with STGD (Lewis
et al. 1999; Maugeri et al. 1999; Rivera et al. 2000 [in
this issue]; Simonelli et al. 2000).
Subsequently, several cases were reported in which
ABCR mutations segregated with retinal dystrophies of
substantially different phenotype, such as autosomal re-
cessive cone-rod dystrophy (arCRD) (Cremers et al.
1998; Rozet et al. 1998) and autosomal recessive reti-
nitis pigmentosa (arRP) (Cremers et al. 1998; Martinez-
Mir et al. 1998; Rozet et al. 1999). arCRD and arRP
have been characterized as groups of genetically het-
erogeneous diseases in which several loci have been im-
plicated by linkage (RetNet Retinal Information Net-
work). Clinical heterogeneity of these disorders further
complicates the assessment of genetic determinants of
each disease entity. Cone-rod dystrophy is characterized
by more prominent cone degeneration, which, in the
electroretinogram (ERG), is distinguished by more-dis-
tinctive reduction of the photopic cone b-wave ampli-
tude than the scotopic (rod b-wave) amplitude, com-
pared with rod degeneration. Conversely, RP affects
predominantly rod photoreceptors, the scotopic ERG is
more severely reduced than the photopic ERG, and pa-
tients present with night blindness and loss of peripheral
vision.
In all studies, disease-associated ABCR alleles have
revealed an extraordinary heterogeneity (Allikmets et
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al. 1997b; Rozet et al. 1998; Fishman et al. 1999; Lewis
et al. 1999; Maugeri et al. 1999; Simonelli et al. 2000),
as demonstrated also in the German population, re-
ported by Rivera et al. (2000) in this issue of the Journal.
The current tally of allABCR alleles suggests350–400
ABCR variants (author’s unpublished data), making
the heterogeneity of ABCR comparable to that of an-
other member of the ABC superfamily, the cystic fibrosis
transmembrane conductance regulator (CFTR) (Rior-
dan et al. 1989). What makes ABCR an even more
difficult diagnostic target than CFTR is that, across all
populations studied, the most-frequent disease-associ-
ated ABCR alleles—for example, G1961E, G863A/
delG863, and A1038V—have been described in ∼10%
of patients with STGD, whereas the delF508 allele of
CFTR accounts for close to 70% of all cystic fibrosis
alleles (Zielenski and Tsui 1995).
On the basis of these findings, several investigators
have proposed a model that suggests a direct correlation
between the continuum of disease phenotypes and re-
sidual ABCR activity/function (van Driel et al. 1998;
Allikmets 1999; Lewis et al. 1999; Maugeri et al. 1999;
Shroyer et al. 1999). According to the predicted effect
on the ABCR transport function, Maugeri et al. clas-
sified ABCRmutant alleles as “mild,” “moderate,” and
“severe” (Maugeri et al. 1999). Different combinations
of these were predicted to result in distinct phenotypes
in a continuum of disease manifestations, the severity
of disease manifestation being inversely proportional to
the residual ABCR activity. On the basis of several as-
sumptions, such as the predicted frequency of ABCR
alleles in the general population and documented prev-
alences of different disease phenotypes, Maugeri et al.
estimated the incidence of retinal degenerations caused
by combinations of ABCR alleles (Maugeri et al. 1999).
Several recent studies, including the two in this issue,
confirm and expand the proposed model (Maugeri et
al. 2000 [in this issue]; Rivera et al. 2000 [in this issue]).
These studies make three important points regarding
the role ofABCR in retinal disease. First, in an extension
of its earlier study, the laboratory of Frans Cremers has
determined the major role of mutant ABCR alleles in
arCRD (Maugeri et al. 2000 [in this issue]). This
groundbreaking discovery of the major genetic com-
ponent in a prominent fraction of retinal disease distin-
guishes arCRD as a disorder predominantly caused by
genetic defects in one gene. This finding argues against
the former assumption that arCRDs represent a genet-
ically heterogeneous entity similar to arRPs (RetNet
Retinal Information Network). It not only offers new
possibilities for disease classification and diagnostics but
also significantly advances possible approaches for
treatment and prevention of this disorder. Second, both
studies have identified a frequent, complex allele,
L541P/A1038V, in patients of German origin who have
both STGD and CRD (Maugeri et al. 2000 [in this
issue]; Rivera et al. 2000 [in this issue]). ComplexABCR
alleles are not uncommon in Stargardt disease (Lewis
et al. 1998). This is a third instance in which an “eth-
nic group–specific” ABCR allele has been discovered.
The earlier study by Maugeri et al. had defined the
2588GrC variant resulting in a dual effect, G863A/
delG863, as a founder mutation in northern-European
patients with STGD (Maugeri et al. 1999). Another
ABCR allele, T1428M, which is very rare in popula-
tions of European descent, is apparently frequent (∼8%)
in the Japanese general population (Kuroiwa et al.
1999). These findings have a prominent influence on
population-genetic studies that rely on ABCR allele fre-
quencies (see below). In addition, the complexity of the
genotype/phenotype–correlation studies in ABCR-re-
lated retinal dystrophies is underlined by the fact that
two patients homozygous for the L541P/A1038V allele
were diagnosed with CRD and STGD (Maugeri et al.
2000 [in this issue]; Rivera et al. 2000 [in this issue]).
Third, the study by Maugeri et al. suggests that we
revisit our current knowledge about the molecular ge-
netics of arRP. The prediction that ABCR alleles are
responsible for ∼8% of arRP, making it the most prom-
inent cause of the autosomal recessive form of RP, seems
reasonable and warrants further investigation.
ABCR in Age-Related Macular Degeneration (AMD)
The summarized data listed above establish allelic var-
iation in ABCR as the most prominent cause of retinal
dystrophies with Mendelian inheritance patterns. The
latest estimates suggest that the carrier frequency of
ABCR alleles in the general population is close to 5%
(Maugeri et al. 1999; J. R. Lupski, personal communi-
cation). This brings us to the hottest topic of ophthalmic
genetics—the role of heterozygous ABCR alleles in a
complex trait, AMD (also designated “ARMD2” [MIM
153800]). AMD, as a typical late-onset complex dis-
order, is caused by a combination of genetic and envi-
ronmental factors. Its prevalence increases with age;
among persons of age 75 years, mild or early forms
occur in nearly 30%, and advanced forms in ∼7%, of
the population (Klein et al. 1992; Vingerling et al. 1995).
Consequently, various forms of AMD affect 110 million
individuals in the United States alone. The Vision Re-
search—A National Plan: 1999–2003 Web site has es-
timated that “with growth in the aged population, age-
related macular degeneration (AMD) will become a
more prevalent cause of blindness than both diabetic
retinopathy and glaucoma combined.” Not surprisingly,
every effort is made to decipher the genetic components
of AMD, and news from this research field gets partic-
ular attention.
In 1997, a joint study by four laboratories suggested
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Table 1
Meta-analysis of Published Data on Two ABCR Alleles
STUDY
D2177N G1961Ea
No. of Cases No of. Controls P (OR [95% CI])b No. of Cases No. of Controls P (OR [95% CI])b
Allikmets et al. (1997a) 7/167 1/220 .012 6/167 0/220 .006
ABCR Consortium 2000 21/1,189 8/1,258 .005 19/1,218 4/1,258 .0008
Stone et al. (1998) 2/182 0/96 .42 1/182 0/96 .65
De La Paz et al. (1999) 2/164 0/56 .55 NA NA NA
McNeil et al. (2000) 5/177 0/150 .045 2/177 0/150 .29
Overall 37/1,879 9/1,780 !.0001 (3.9 [1.9–8.0]) 28/1,744 4/1,724 !.0001 (7.0 [2.5–20])
a NA p not applicable.
b ORp odds ratio; CIp confidence interval. P values were calculated from the one-sided Fisher’s exact test, and odds ratios were calculated
from the exact conditional hypergeometric distribution (Mehta and Patel 1995).
association of heterozygous ABCR alleles with the
AMD phenotype (Allikmets et al. 1997a). This “clas-
sical” case-control study of 167 patients with AMD and
220 controls found, in 16% of patients, ABCR alter-
ations that were interpreted as being associated with the
disease phenotype, since they were found in !1% of
controls. Most alterations resulted in rare missense mu-
tations, some of which had also been found in patients
with STGD1 (Allikmets et al. 1997a). Subsequently, sev-
eral reports disputed the conclusions of that study, stat-
ing that they were unable to replicate these findings and,
therefore, to confirm the association (Stone et al. 1998;
De La Paz et al. 1999; Kuroiwa et al. 1999). Rivera et
al. come to similar conclusions in their current article
(Rivera et al. 2000 [in this issue]). Problems with rep-
lication of an association study of a complex disease
are not unexpected, and discussion of the topic is be-
yond the scope of this editorial (e.g., see Long and Lang-
ley 1999; O’Donovan and Owen 1999). In short, dif-
ficulties arise mainly because of small sample size in
studies of rare variants with modest effect on a complex
trait.
Our hypothesis-generating finding that heterozygous
ABCR mutations may increase susceptibility to AMD
was recently tested by an expanded collaborative study
that included 15 centers in Europe and North America
(ABCR Consortium; Allikmets 2000). In that study, the
two most common AMD-associated variants, G1961E
and D2177N, were genotyped in 1,218 unrelated pa-
tients with AMD and in 1,258 reportedly unaffected,
matched controls. Together, these two nonconservative
amino acid changes were found in one allele of ABCR
in 40 patients (∼3.4%) and in 12 controls (∼0.95%), a
statistically significant difference ( ) (AllikmetsP ! .0001
2000). The risk of AMD was estimated to be increased
approximately threefold in carriers of D2177N and ap-
proximately fivefold in carriers of G1961E. In the con-
text of common complex disorders, this represents an
important contribution to the disease load. Since AMD
affects millions of people worldwide, and since the de-
scribed mutations represent only 2 of 13 reported else-
where (Allikmets et al. 1997a), the number of people
at increased risk of developing age-relatedmaculopathy,
as carriers of variant ABCR alleles, is substantial.
To further explain and, it is hoped, resolve the
“ABCR controversy,” I offer the following meta-anal-
ysis of published data on the two most frequent ABCR
variants (table 1). Data from Rivera et al.’s study of
these variants are not separated in the table, since they
had been included in the ABCR Consortium study (Al-
likmets 2000). It is apparent that the main reason for
the controversial interpretation of the data is the small
sample size in individual studies. If analyzed separately,
none of the studies, with the exception of that by Al-
likmets et al. (1997a), yields statistically significant re-
sults. A substantial increase in the sample size, as in the
consortium study or in the proposed meta-analysis, re-
sults in substantial increase of power of statistical anal-
ysis. Resulting P values, as well as relative risk estimates,
leave no doubt that the association is statistically sig-
nificant. Note that the relative risk estimates calculated
on the basis of the meta-analysis are also increased com-
pared with those in the consortium study (Allikmets
2000) and are estimated at ∼4 for the D2177Nmutation
and at ∼7 for the G1961E variant.
These analyses, once again, clearly demonstrate the
need for large cohorts of cases and matched controls
for association studies of rare alleles. When all available
data are considered, heterozygous ABCR alleles are es-
timated to increase susceptibility to AMD in ∼8%–10%
of all cases. However, this estimate has to be assessed
with caution, since the analysis of ABCR variation in
AMD is far from complete. The reader has to be re-
minded that, even in Stargardt disease, ∼30%–40% of
disease-associated ABCR alleles go undetected (Allik-
mets 1999). In addition, as emphasized above, founder
alleles in some ethnic groups can seriously affect the
analysis, suggesting that large, multicenter-based studies
of matched cases and controls are the only alternative
method to achieve statistical significance. Consorted
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study design also helps minimize the confounding effect
of population stratification, the most serious reason for
spurious associations (for an explanation, refer to Al-
likmets 2000). Until recently, designs with family-based
controls, as in various modifications of transmission/
disequilibrium tests (TDTs [Spielman et al. 1993]), were
considered a panacea for association studies. However,
not only are TDTs (even those using sibs instead of
parents) very difficult to perform on late-onset disor-
ders, but the effort may be of limited value, since the
effect of population stratification may have been over-
estimated (Morton and Collins 1998) and since family-
based control data lead to substantial loss of power for
detection of linkage disequilibrium, compared with
studies of case-control variety (Schaid and Rowland
1998). Instead, the genotyping of a sufficient number
of independent single-nucleotide polymorphisms (SNPs)
in matched cases and controls is likely to maintain the
robustness of a more powerful, large, multiethnic case-
control study (for review, see Risch 2000). Application
of alternative approaches to decipher the genetic com-
ponent of AMD, such as full genome scans by linkage,
has yielded disappointing results, at least in the hetero-
geneous U.S. population (Weeks et al. 2000). These re-
sults were expected, since it was predicted quite some
time ago (Risch and Merikangas 1996) that, in the ab-
sence of “major” loci, a likely scenario for AMD, link-
age analysis would have limited power in comparison
with association studies of candidate genes.
Functional Studies of ABCR
Data presented in the previous section, on the issue of
allelic association of ABCRwith AMD, should convince
even the most skeptical reviewers. However, for those
who are still not persuaded, supporting functional evi-
dence is provided as follows. The ABCR protein was
first described, in the 1970s, as a large component of
photoreceptor outer-segment disk rims (Papermaster et
al. 1976, 1978). Hence, it was called a “rim protein”
(RimP) for the next 20 years. Only in 1997 was the
encoding gene cloned and characterized as a member of
the ABC-transporter superfamily, suggesting a transport
function of some substrate in photoreceptor outer seg-
ments (Allikmets et al. 1997b; Illing et al. 1997). All-
trans retinal, the isoform of rhodopsin chromophore,
was identified as a potential substrate of ABCR, on the
basis of its ability to stimulate ATP hydrolysis by re-
constituted ABCR protein in vitro, suggesting that ret-
inal could also be the in vivo substrate for ABCR (Sun
et al. 1999). Studies of Abcr-knockout mice fully sup-
ported this hypothesis, proposing ABCR as a “flippase”
of the protonated complex of all-trans retinal and phos-
phatidylethanolamine (N-retinylidene-PE) (Weng et al.
1999). Mice lacking the functional Abcr gene demon-
strated delayed dark adaptation, increased all-trans ret-
inal after light exposure, elevated phosphatidyletha-
nolamine in rod outer segments, accumulation of the
protonated N-retinylidene-PE complex, and striking
deposition of a major lipofuscin fluorophore (A2-E) in
the RPE. On the basis of these findings, it was suggested
that the ABCR-mediated retinal degeneration may result
from “poisoning” of the RPE because of A2-E accu-
mulation, with secondary photoreceptor degeneration
due to loss of the RPE support role (Weng et al. 1999).
A2-E, a pyridinium bis-retinoid, which is derived from
two molecules of vitamin A aldehyde and one molecule
of ethanolamine, has been characterized as one of the
major components of RPE lipofuscin. Accumulation of
lipofuscin in the macular region of RPE is characteristic
of aging eyes and is the hallmark of both STGD1 and
AMD.
Together, these data define ABCR as the “rate keeper”
of the transport of retinal in the visual cycle. ABCR is
apparently not absolutely essential for this process, since
individuals completely lacking the functional protein
(e.g., some patients with arRP) maintain some eyesight
for several years. Over time, however, even mild dys-
function of ABCR affects vision irreparably. Most re-
cently, intriguing data were obtained, from studies of
Abcr/ heterozygous mice, that fully support ABCR
involvement in AMD (Mata et al. 2000): a phenotype
similar to that seen in Abcr knockouts (A2E accumu-
lation in the RPE, etc.) was described in heterozygous
mice, but its manifestation occurred at a slower, age-
related, rate. The distinct, AMD-resembling phenotype
in the Abcr/mouse model suggests that humans het-
erozygous for ABCR mutations may be predisposed to
A2E accumulation and concomitant retinal or macular
disease (Mata et al. 2000).
Remarkable allelic heterogeneity of the ABCR gene
has substantially complicated genetic analysis of its in-
volvement in retinal disease, especially in the AMD
complex trait. In a situation in which a modest effect
of a mutation can be estimated only by association anal-
ysis, the crucial question of the functional significance
of a particular sequence variant often remains unan-
swered, generating sometimes unnecessary speculations.
It is not enough to classify mutations as “possibly” or
“probably” disease causing, only on the basis of cir-
cumstantial evidence—for example, on the basis of a
predicted effect of an amino acid change on the protein
function. Development of an ABCRmutagenesis system
that allows the determination of the actual effect of
ABCR variants have on the protein function has there-
fore been highly anticipated.
Most recent data from photoaffinity-labeling and
ATPase-activity experiments in Jeremy Nathans’ labo-
ratory (Sun et al. 2000) have dramatically advanced our
knowledge in this field. In addition to determining the
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effect of ∼40 ABCR mutations, these elegant experi-
ments offer new evidence directly relevant to our dis-
cussion. For example, they demonstrate that both
ABCR variants analyzed in the consortium study,
G1961E and D2177N, affect the protein function in
vitro. The mutant G1961E protein, produced after the
transfection of human embryonic kidney (293) cells
with cloned cDNA, exhibits both several-fold–lower
binding of 8-azido-ATP and dramatic inhibition of ATP-
ase activity by retinal, compared with the wild-type
ABCR protein. The D2177N variant had no effect on
8-azido-ATP binding but exhibited a reproducible ele-
vation in ATPase activity, relative to the wild type (Sun
et al. 2000). Consequently, the ABCR variants deemed
to be associated with the AMD phenotype are not anon-
ymous SNPs but, rather, are mutations affecting ABCR
function. These results will also challenge several sug-
gestions (Fishman et al. 1999; Lotery et al. 2000) that
G1961E, themutationmost frequently found in patients
with STGD and/or AMD, is indeed a benign variant in
linkage disequilibrium with another disease-causing
mutation.
Another issue that has been clarified is that of the
functional significance of the G863A/delG863 variant.
This variant is the most common single allele among
northern-European patients with STGDand is also pres-
ent in ∼3% of the general population (Maugeri et al.
1999). Although Maugeri et al. classified this variant as
a “mild” mutation, its role in retinal pathology has been
disputed because of its high (11%) frequency in the
general population. Data by Sun et al. clearly demon-
strate a profound biochemical defect caused by either
version of this mutation, effectively supporting the con-
clusions of the earlier study. Last, both mutations found
on the “German” complex allele, L541P and A1038V,
even if analyzed separately, render the ABCR protein
defective (Sun et al. 2000). In summary, functional stud-
ies fully support the proposed genotype/phenotype
model of ABCR and offer several tools to advance our
knowledge about the role of ABCR in chorioretinal
disease.
Outlook
The scientific progress in the determination of the role
of the ABCR gene in retinal pathology has been re-
markable. We have significantly expanded our knowl-
edge of the extensive range of phenotypes caused by
various combinations of ABCR mutations. ABCR re-
search has led to the formation of multicenter studies,
encompassing large cohorts of ethnically diverse sam-
ples. It is now known that ABCR functions as the trans-
porter of N-retinylidene-PE, and there is an in vitro sys-
tem(s) to study functional implications of all mutations.
Finally, there is a mouse model that accurately repro-
duces many features of human disorders. Considering
all the above, I see no reason why the scientific excite-
ment that has followed ABCR research cannot trans-
form into an equal excitement for people who would
benefit the most—those affected with different forms of
retinal disease. Our efforts should now be moved to the
next stage of research, directed toward the finding of
therapeutic solutions for ABCR-mediated chorioretinal
disease, by either improving the transport function of
ABCR or preventing accumulation of toxic products re-
sulting from ABCR malfunction.
Acknowledgments
The author sincerely appreciates helpful discussions and
critical review of the manuscript by J. Lupski and M. Dean,
as well as useful suggestions from F. Cremers. Support by the
Ruth and Milton Steinbach Fund and a Research to Prevent
Blindness Career Development Award is gratefully ac-
knowledged.
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/omim/ (for STGD1 [MIM 248200]; and
ARMD2 [MIM 153800])
RetNet Retinal Information Network, http://www.sph.uth.tmc
.edu/Retnet/home.htm
Vision Research—A National Plan: 1999–2003, http://www.
nei.nih.gov/publications/plan/plan.htm
References
Allikmets R (1999) Molecular genetics of age-related macular
degeneration: current status. Eur J Ophthalmol 9:255–265
——— (2000) Further evidence for an association of ABCR
alleles with age-related macular degeneration. Am J Hum
Genet 67:487–491
Allikmets R, Shroyer NF, Singh N, Seddon JM, Lewis RA,
Bernstein PS, Peiffer A, Zabriskie NA, Li Y, Hutchinson A,
Dean M, Lupski JR, Leppert M (1997a) Mutation of the
Stargardt disease gene (ABCR) in age-related macular de-
generation. Science 277:1805–1807
Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A,
Chidambaram A, Gerrard B, Baird L, Stauffer D, Peiffer A,
Rattner A, Smallwood P, Li Y, Anderson KL, Lewis RA,
Nathans J, Leppert M, Dean M, Lupski JR (1997b) A
photoreceptor cell-specific ATP-binding transporter gene
(ABCR) is mutated in recessive Stargardt macular dys-
trophy. Nat Genet 15:236–246
Anderson KL, Baird L, Lewis RA, Chinault AC, Otterud B,
Leppert M, Lupski JR (1995) A YAC contig encompassing
the recessive Stargardt disease gene (STGD) on chromosome
1p. Am J Hum Genet 57:1351–1363
Azarian SM, Travis GH (1997) The photoreceptor rim protein
798 Am. J. Hum. Genet. 67:793–799, 2000
is an ABC transporter encoded by the gene for recessive
Stargardt’s disease (ABCR). FEBS Lett 409:247–252
Cremers FP, van de Pol DJ, van Driel M, den Hollander AI,
van Haren FJ, Knoers NV, Tijmes N, Bergen AA, Rohr-
schneider K, Blankenagel A, Pinckers AJ, Deutman AF,
Hoyng CB (1998) Autosomal recessive retinitis pigmentosa
and cone-rod dystrophy caused by splice site mutations in
the Stargardt’s disease gene ABCR. Hum Mol Genet 7:
355–362
De La Paz MA, Guy VK, Abou-Donia S, Heinis R, Bracken
B, Vance JM, Gilbert JR, Gass JD, Haines JL, Pericak-Vance
MA (1999) Analysis of the Stargardt disease gene (ABCR)
in age-related macular degeneration. Ophthalmology 106:
1531–1536
Fishman GA, Stone EM, Grover S, Derlacki DJ, Haines HL,
Hockey RR (1999) Variation of clinical expression in pa-
tients with Stargardt dystrophy and sequence variations in
the ABCR gene. Arch Ophthalmol 117:504–510
Illing M, Molday LL, Molday RS (1997) The 220-kDa rim
protein of retinal rod outer segments is a member of
the ABC transporter superfamily. J Biol Chem 272:10303–
10310
Kaplan J, Gerber S, Larget-Piet D, Rozet JM, Dollfus H, Du-
fier JL, Odent S, Postel-Vinay A, Janin N, Briard ML, Fre´zal
J, Munnich A (1993) A gene for Stargardt’s disease (fundus
flavimaculatus) maps to the short arm of chromosome 1.
Nat Genet 5:308–311
Klein R, Klein BE, Linton KL (1992) Prevalence of age-relat-
ed maculopathy: the Beaver Dam eye study. Ophthalmology
99:933–943
Kuroiwa S, Kojima H, Kikuchi T, Yoshimura N (1999) ATP
binding cassette transporter retina genotypes and age related
macular degeneration: an analysis on exudative non-familial
Japanese patients. Br J Ophthalmol 83:613–615
Lewis RA, Shroyer NF, Singh N, Allikmets R, Hutchinson A,
Li Y, Lupski JR, Leppert M, Dean M (1999) Genotype/
phenotype analysis of a photoreceptor-specific ATP-binding
cassette transporter gene, ABCR, in Stargardt disease. Am
J Hum Genet 64:422–434
Long AD, Langley CH (1999) The power of association studies
to detect the contribution of candidate genetic loci to var-
iation in complex traits. Genome Res 9:720–731
Lotery AJ, Heon E, Guymer R, Billingsley G, McNeil R, Cain
M, Sui H, Haines H, Sheffield VC, Stone EM (2000) Star-
gardt disease in patients of Somalian ancestry [ARVO Ab-
stract]. Invest Ophthalmol Vis Sci 41:S143
Martinez-Mir A, Paloma E, Allikmets R, Ayuso C, del Rio T,
Dean M, Vilageliu L, Gonzalez-Duarte R, Balcells S (1998)
Retinitis pigmentosa caused by a homozygous mutation in
the Stargardt disease gene ABCR. Nat Genet 18:11–12
Mata NL, Weng J, Travis GH (2000) Biogenesis of lipofuscin
in retina and RPE of ABCR knockout mice and humans
with ABCR-mediated macular degenerations. [ARVO ab-
stract]. Invest Ophthalmol Vis Sci 41:S144
Maugeri A, Klevering BJ, Rohrschneider K, Blankenagel A,
Brunner HG, Deutman AF, Hoyng CB, Cremers FPM (2000)
Mutations in the ABCA4 (ABCR) gene are the major cause
of autosomal recessive cone-rod dystrophy. Am J Hum Ge-
net 67:960–966 (in this issue)
Maugeri A, van Driel MA, van de Pol DJ, Klevering BJ, van
Haren FJ, Tijmes N, Bergen AA, Rohrschneider K, Blan-
kenagel A, Pinckers AJ, Dahl N, Brunner HG, Deutman AF,
Hoyng CB, Cremers FP (1999) The 2588GrC mutation in
the ABCR gene is a mild frequent founder mutation in the
western European population and allows the classification
of ABCR mutations in patients with Stargardt disease. Am
J Hum Genet 64:1024–1035
McNeil RJ, Baird PNS, Cain MS, Allen PJ, McCarty CA, Guy-
mer RH (2000) Is there a role for the ABCR Stargardt’s gene
in AMD? [ARVO abstract]. Invest Ophthalmol Vis Sci 41:
S144
Mehta C, Patel N (1995) StatXact3 for Windows user manual.
Cytel Software, Cambridge, MA
Morton NE, Collins A (1998) Tests and estimates of allelic
association in complex inheritance. Proc Natl Acad Sci USA
95:11389–11393
O’DonovanMC, OwenMJ (1999) Candidate-gene association
studies of schizophrenia. Am J Hum Genet 65:587–592
Papermaster DS, Converse CA, Zorn M (1976) Biosynthetic
and immunochemical characterization of large protein in
frog and cattle rod outer segment membranes. Exp Eye Res
23:105–115
Papermaster DS, Schneider BG, Zorn MA, Kraehenbuhl JP
(1978) Immunocytochemical localization of a large intrinsic
membrane protein to the incisures and margins of frog rod
outer segment disks. J Cell Biol 78:415–425
Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R,
Grzelczak Z, Zielenski J, et al (1989) Identification of the
cystic fibrosis gene: cloning and characterization of com-
plementary DNA. Science 245:1066–1073
Risch NJ (2000) Searching for genetic determinants in the new
millennium. Nature 405:847–856
Risch N, Merikangas K (1996) The future of genetic studies
of complex human diseases. Science 273:1516–1517
Rivera A, White K, Stohr H, Steiner K, Hemmrich N, Grimm
T, Jurklies B, Lorenz B, Scholl HPN, Apfestedt-Sylla E, We-
ber BHF (2000) A comprehensive survey of sequence vari-
ation in the ABCA4 (ABCR) gene in Stargardt disease and
age-related macular degeneration. Am J Hum Genet 67:
800–813 (in this issue)
Rozet JM, Gerber S, Ghazi I, Perrault I, Ducroq D, Souied E,
Cabot A, Dufier JL, Munnich A, Kaplan J (1999) Mutations
of the retinal specific ATP binding transporter gene (ABCR)
in a single family segregating both autosomal recessive ret-
initis pigmentosa RP19 and Stargardt disease: evidence of
clinical heterogeneity at this locus. J Med Genet 36:447–
451
Rozet JM, Gerber S, Souied E, Perrault I, Chatelin S, Ghazi I,
Leowski C, Dufier JL, Munnich A, Kaplan J (1998) Spec-
trum of ABCR gene mutations in autosomal recessive mac-
ular dystrophies. Eur J Hum Genet 6:291–295
Schaid DJ, Rowland C (1998) Use of parents, sibs, and un-
related controls for detection of associations between genetic
markers and disease. Am J Hum Genet 63:1492–1506
Shroyer NF, Lewis RA, Allikmets R, Singh N, DeanM, Leppert
M, Lupski JR (1999) The rod photoreceptor ATP-binding
cassette transporter gene, ABCR, and retinal disease: from
monogenic to multifactorial. Vision Res 39:2537–2544
Simonelli F, Testa F, de Crecchio G, Rinaldi E, Hutchinson A,
Atkinson A, Dean M, D’Urso M, Allikmets R (2000) New
ABCR mutations and clinical phenotype in Italian patients
Allikmets: Invited Editorial 799
with Stargardt disease. Invest Ophthalmol Vis Sci 41:892–
897
Spielman RS, McGinnis RE, Ewens WJ (1993) Transmission
test for linkage disequilibrium: the insulin gene region and
insulin-dependent diabetes mellitus (IDDM). Am J HumGe-
net 52:506–516
Stone EM, Webster AR, Vandenburgh K, Streb LM, Hockey
RR, Lotery AJ, Sheffield VC (1998) Allelic variation in
ABCR associated with Stargardt disease but not age- related
macular degeneration. Nat Genet 20:328–329
Sun H, Molday RS, Nathans J (1999) Retinal stimulates ATP
hydrolysis by purified and reconstituted ABCR, the photo-
receptor-specific ATP-binding cassette transporter respon-
sible for Stargardt disease. J Biol Chem 274:8269–8281
Sun H, Smallwood PM, Nathans J (2000) Biochemical defects
in ABCR protein variants associated with human retinop-
athies. Nat Genet (in press)
van Driel MA, Maugeri A, Klevering BJ, Hoyng CB, Cremers
FP (1998) ABCR unites what ophthalmologists divide(s).
Ophthalmic Genet 19:117–122
Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmer-
ing M, Kramer CF, de Jong PT (1995) The prevalence of
age-related maculopathy in the Rotterdam Study. Ophthal-
mology 102:205–210
Weeks DE, Conley YP, Mah TS, Paul TO, Morse L, Ngo-
Chang J, Dailey JP, Ferrell RE, Gorin MB (2000) A full
genome scan for age-related maculopathy. Hum Mol Genet
22:1329–1349
Weng J, Mata NL, Azarian SM, Tzekov RT, Birch DG, Travis
GH (1999) Insights into the function of Rim protein in pho-
toreceptors and etiology of Stargardt’s disease from the phe-
notype in abcr knockout mice. Cell 98:13–23
Zielenski J, Tsui LC (1995) Cystic fibrosis: genotypic and phe-
notypic variations. Annu Rev Genet 29:777–807
